David C Kaslow

David C Kaslow

UNVERIFIED PROFILE

Are you David C Kaslow?   Register this Author

Register author
David C Kaslow

David C Kaslow

Publications by authors named "David C Kaslow"

Are you David C Kaslow?   Register this Author

57Publications

1301Reads

34Profile Views

HIV immunoprophylaxis: preparing the pathway from proof of concept to policy decision and use.

Lancet HIV 2020 Feb 27;7(2):e141-e148. Epub 2019 Nov 27.

Wits Reproductive Health and HIV Research Institute, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3018(19)30294-2DOI Listing
February 2020

Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016.

Vaccine 2019 Nov 3;37(50):7315-7327. Epub 2017 Mar 3.

Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2016.10.090DOI Listing
November 2019

Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016.

Vaccine 2019 Nov 14;37(50):7355-7362. Epub 2017 Mar 14.

Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2017.02.068DOI Listing
November 2019

WHO consultation on ETEC and Shigella burden of disease, Geneva, 6-7th April 2017: Meeting report.

Vaccine 2019 Nov 17;37(50):7381-7390. Epub 2018 Jan 17.

Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2017.10.011DOI Listing
November 2019

Antibody-Dependent, Gamma Interferon-Independent Sterilizing Immunity Induced by a Subunit Malaria Vaccine.

Infect Immun 2019 10 19;87(10). Epub 2019 Sep 19.

Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/IAI.00236-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759290PMC
October 2019

Maternal interventions vigilance harmonization in low- and middle-income countries: Stakeholder meeting report; Amsterdam, May 1-2, 2018.

Vaccine 2019 May 4;37(20):2643-2650. Epub 2019 Apr 4.

Global Medicines Program, Schools of Pharmacy and Public Health, BOX 357631, University of Washington, Seattle, WA 98195-7631, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0264410X193040
Publisher Site
http://dx.doi.org/10.1016/j.vaccine.2019.03.060DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546955PMC
May 2019

WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting held on 12-13 December 2016.

Vaccine 2018 06 26;36(24):3397-3405. Epub 2018 Feb 26.

Group A Streptococcal Research Group, Murdoch Children's Research Institute, Melbourne 3052, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0264410X183025
Publisher Site
http://dx.doi.org/10.1016/j.vaccine.2018.02.068DOI Listing
June 2018

Vaccines to Accelerate Malaria Elimination and Eventual Eradication.

Cold Spring Harb Perspect Med 2017 Sep 1;7(9). Epub 2017 Sep 1.

PATH Malaria Vaccine Initiative, Washington, D.C. 20001.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/cshperspect.a025627DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580511PMC
September 2017

Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015.

Vaccine 2016 06 15;34(26):2865-2869. Epub 2016 Mar 15.

Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2016.02.078DOI Listing
June 2016

Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children.

N Engl J Med 2016 Jun;374(26):2519-29

From the Kenya Medical Research Institute (KEMRI)-Wellcome Trust Programme, Kilifi, Kenya (A.O., G.F., J.W., G.N., P.N., K.M., P.B.); Ifakara Health Institute, Bagamoyo, Tanzania (A.O.); the Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom (G.F., K.M., P.B.); GlaxoSmithKline Vaccines, Wavre, Belgium (A.L., M.L.); and PATH, Seattle (D.C.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1515257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962898PMC
June 2016

WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015.

Vaccine 2016 Jan 20;34(2):190-197. Epub 2015 Jun 20.

Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2015.05.093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858870PMC
January 2016

RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap.

Vaccine 2015 Dec 1;33(52):7425-32. Epub 2015 Oct 1.

GSK Vaccines, Avenue Fleming, 20, Wavre, 1300, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2015.09.061DOI Listing
December 2015

Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities.

Vaccine 2013 Apr;31 Suppl 2:B233-43

PATH Malaria Vaccine Initiative, Washington, DC 20001-2621, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2013.02.040DOI Listing
April 2013

Clostridium difficile and methicillin-resistant Staphylococcus aureus: emerging concepts in vaccine development.

Annu Rev Med 2011 ;62:201-15

Merck Research Laboratories, Merck & Co. Inc., North Wales, Pennsylvania 19454, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-med-051109-101544DOI Listing
May 2011

Approaches to malaria vaccine development using the retrospectroscope.

Infect Immun 2009 Aug 18;77(8):3130-40. Epub 2009 May 18.

Department of Medicine, University of Illinois at Chicago, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/IAI.00122-09DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715670PMC
August 2009

Biological feasibility of developing prophylactic vaccines for viral pathogens: incubation period as a critical parameter.

Authors:
David C Kaslow

Hum Vaccin 2007 Jan-Feb;3(1):1-7. Epub 2007 Jan 17.

Merck Research Laboratories, North Wales, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.3.1.3519DOI Listing
March 2007

Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines.

Vaccine 2006 Mar 2;24(11):1921-7. Epub 2005 Nov 2.

Malaria Program, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2005.10.041DOI Listing
March 2006

A potential disruptive technology in vaccine development: gene-based vaccines and their application to infectious diseases.

Authors:
David C Kaslow

Trans R Soc Trop Med Hyg 2004 Oct;98(10):593-601

Vical Incorporated, 10390 Pacific Center Court, San Diego, CA 92121-4340, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trstmh.2004.03.007DOI Listing
October 2004

The effects of varying exposure to malaria transmission on development of antimalarial antibody responses in preschool children. XVI. Asembo Bay Cohort Project.

J Infect Dis 2003 Jun 12;187(11):1756-64. Epub 2003 May 12.

Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341-3717, USA.

View Article

Download full-text PDF

Source
https://academic.oup.com/jid/article-lookup/doi/10.1086/3752
Publisher Site
http://dx.doi.org/10.1086/375241DOI Listing
June 2003

Development of an adenovirus-shedding assay for the detection of adenoviral vector-based vaccine and gene therapy products in clinical specimens.

Hum Gene Ther 2003 Jan;14(1):25-36

Department of Virus & Cell Biology, Merck Research Laboratories, Merck & Co., Inc. West Point, PA 19486, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/10430340360464688DOI Listing
January 2003

Transmission-blocking vaccines.

Authors:
David C Kaslow

Chem Immunol 2002 ;80:287-307

Merck Research Laboratories, West Point, Pa., USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000058850DOI Listing
July 2002

Aotus New World monkeys: model for studying malaria-induced anemia.

Blood 2002 May;99(10):3863-6

Malaria Vaccines Section and Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda , MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.v99.10.3863DOI Listing
May 2002

A high malaria reinfection rate in children and young adults living under a low entomological inoculation rate in a periurban area of Bamako, Mali.

Am J Trop Med Hyg 2002 Mar;66(3):310-3

Malaria Research and Training Center, Departement d'Epidemiologie des Affections Parasitaires, Faculté de Médicine, de Pharmacie et d'Odonto-Stomatologie, Université du Mali, Bamako.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4269/ajtmh.2002.66.310DOI Listing
March 2002

Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.

Infect Immun 2002 Feb;70(2):692-701

Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0425, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC127724PMC
http://dx.doi.org/10.1128/iai.70.2.692-701.2002DOI Listing
February 2002

A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum.

Proc Natl Acad Sci U S A 2002 Jan 18;99(1):339-44. Epub 2001 Dec 18.

Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Rockville, MD 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.012590199DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC117562PMC
January 2002